TO WHAT EXTENT ARE BASELINE CHARACTERISTICS IN BIOLOGIC-EXPERIENCED PATIENTS WITH PSORIATIC ARTHRITIS ASSOCIATED WITH ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AT WEEK 24 OF GUSELKUMAB TREATMENT: A POST HOC ANALYSIS OF THE PHASE IIIB COSMOS CLINICAL TRIAL

被引：0
|
作者：
Tillett, W. [1 ]
Ohrndorf, S. [2 ]
Ramirez, J. [3 ]
Neuhold, M. [4 ]
Wapenaar, R. [5 ]
Theander, E. [6 ]
Contre, C. [7 ]
Sharaf, M. [8 ]
Shawi, M. [9 ]
Vis, M. [10 ]
机构：
[1] Univ Bath, Royal Natl Hosp Rheumat Dis, Bath, Avon, England
[2] Charite Univ Med Berlin, Berlin, Germany
[3] Hosp Univ Clin, Barcelona, Spain
[4] Janssen Cilag, Zug, Switzerland
[5] Janssen Cilag BV, Breda, Netherlands
[6] Janssen Cilag, Solna, Sweden
[7] Janssen Cilag, Issy Les Moulineaux, France
[8] Janssen Cilag, Dubai, U Arab Emirates
[9] Janssen Global Serv LLC, Horsham, PA USA
[10] Erasmus MC, Univ Med Ctr, Rotterdam, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.2624
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1051
引用
收藏
页码：844 / 845
页数：2
相关论文
共 27 条
  • [11] Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
    Ritchlin, Christopher
    Mease, Philip J.
    Boehncke, Wolf-Henning
    Tesser, John
    Chakravarty, Soumya
    Rampakakis, Emmanouil
    Shawi, May
    Schiopu, Elena
    Merola, Joseph
    McInnes, Iain B.
    Deodhar, Atul
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4178 - 4182
  • [12] Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
    Helliwell, Philip
    Bushmakin, Andrew
    Gladman, Dafna
    FitzGerald, Oliver
    Fallon, Lara
    Cappelleri, Joseph
    Hsu, Ming-Ann
    Coates, Laura
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [13] Stringent Disease Activity Control at 2 Years Across Psoriatic Arthritis Domains Irrespective of Baseline Characteristics in Patients Treated with Guselkumab: Post-Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
    Ritchlin, Christopher T.
    Mease, Philip J.
    Boehncke, Wolf-Henning
    Tesser, John
    Chakravarty, Soumya D.
    Rampakakis, Emmanouil
    Shawi, May
    Merola, Joseph F.
    McInnes, Iain B.
    Deodhar, Atul
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB225 - AB225
  • [14] Efficacy of guselkumab in bionaive psoriatic arthritis patients with severe disease activity: post hoc analysis of Phase 3, randomized, double-blind, placebo-controlled study
    Ritchlin, Christopher T.
    Lubrano, Ennio
    Chimenti, Maria Sole
    Leibowitz, Evan
    Sharaf, Mohamed
    Rampakakis, Emmanouil
    Chakravarty, Soumya
    Nantel, Francois
    Lavie, Frederic
    Deodhar, Atul
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [15] Early Fatigue Improvement with Guselkumab Associates with Longer Term Disease Control in Patients with Active Psoriatic Arthritis Reporting Substantial Fatigue: Post Hoc Analyses of a Sub- Population of a Phase 3, Randomized, Controlled Trial of Guselkumab in Biologic-Naive Patients
    Gladman, Dafna
    Baraliakos, Xenofon
    Starr, Michael
    Ranza, Roberto
    Rampakakis, Emmanouil
    Shiff, Natalie
    Nantel, Francois
    Han, Chenglong
    Ostor, Andrew James Knowles
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2796 - 2798
  • [16] Efficacy of Guselkumab in Bionaive Psoriatic Arthritis Patients with Severe Disease Activity: Post-hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
    Ritchlin, Christopher
    Lubrano, Ennio
    Chimenti, Maria Sole
    Leibowitz, Evan
    Sharaf, Mohamed
    Adelakun, Oyediran
    Rampakakis, Emmanouil
    Nantel, Francois
    Lavie, Frederic
    Deodhar, Atul
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 2999 - 3001
  • [17] Domains Contributing to Minimal Disease Activity Non-Achievement in Patients with Psoriatic Arthritis Receiving Golimumab: Post Hoc Analysis of a Phase 3, Randomized, Double-blind, Placebo-controlled Study
    Kavanaugh, Arthur
    Lam, Gordon
    Tam, Lin-Shan
    Shiff, Natalie
    Lee, Youngja
    Perdomo, Ana-Maria Bravo
    Shawi, May
    Hsia, Elizabeth
    Rampakakis, Emmanouil
    Gutierrez, Carlos Enrique Toro
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4170 - 4172
  • [18] Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
    Coates, Laura C.
    Rahman, Proton
    Mease, Philip J.
    Shawi, May
    Rampakakis, Emmanouil
    Kollmeier, Alexa P.
    Xu, Xie L.
    Chakravarty, Soumya D.
    McInnes, Iain B.
    Tam, Lai-Shan
    BMC RHEUMATOLOGY, 2024, 8 (01)
  • [19] Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study
    Laura C. Coates
    Proton Rahman
    Philip J. Mease
    May Shawi
    Emmanouil Rampakakis
    Alexa P. Kollmeier
    Xie L. Xu
    Soumya D. Chakravarty
    Iain B. McInnes
    Lai-Shan Tam
    BMC Rheumatology, 8
  • [20] Neutrophil Levels Associate with Early Improvement in Spinal Pain and Week 24 Multi-Domain Disease Control During Guselkumab Treatment in Active Psoriatic Arthritis: Post Hoc Pooled Analyses of Two Phase 3 Randomized Controlled Trials
    Macleod, Thomas
    Baraliakos, Xenofon
    Rampakakis, Emmanouil
    Chen, Warner
    Van Den Heuvel, Antonius Pieter J.
    Seridi, Loqmane
    Shawi, May
    Lavie, Frederic
    Merola, Joseph F.
    Rahman, Proton
    McGonagle, Dennis
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4409 - 4411
123